Plagiaristic Ugur Sahin and his firm Biontech

Ugur Sahin did not responded to my letters in which I stated Sahin's plagiarism. Thus Sahin wishes to conceal his plagiarism. For example the following patent documents, in which Ugur Sahin is mentioned as „inventor“ and Biontech as „applicant“ are not new and not inventive because of my according prior German patent documents claiming priority worldwide, (and thus Sahin's or Biontech's descriptions can not be patents or can be invalidated if patents would be granted by error of examiners):

1). CA2971950 „Cytokine Fusion Proteins“ (2016, also published as AU2016207955, WO2016112983 and WO2016113395) describes fusion proteins with tumor necrosis factor (TNF) and is not new and not inventive because of my German patent DE10161899 (from 2001) for TNF fusion proteins.

2). SG11201704597W „Agonistic TNF Receptor binding agents“ (2015 and 2016, also published as AU2016205974, CA2969888 and WO2016110584) are also not new and not inventive because of my above mentioned DE10161899.

3). AU2015335054 „Methods and compositions for diagnosis and treatment of cancer“ (especially claim 1, (ribozyme, antisense RNA, other RNA), claim 3 (ligand of a tumor antigen attached to cytotoxin or cytotoxic enzyme), claim 5, 8 (chimeric antibody), 9 (The pharmaceutical composition as claimed in any of claims 5 to 8 which is in the form of a therapeutic or prophylactic tumor vaccine), 18 (chimeric antibody) and 19 (A conjugate between an agent as claimed in claim 18 and a therapeutic effector moiety), 2014, also published as EP3209696, WO2016062323 and WO2016062659) are not new and not inventive because of my German patents DE10161899 (from 2001), DE10161738 (2001), DE19925052 (1999) as well as my patent documents DE10162870 (2001) and DE10160248 (2001).

4). AU2017213515 „Individualized vaccines for cancer“ (especially claim 22 (A vaccine comprising a recombinant polypeptide (!) comprising (!) mutation based neo epitopes, the neo-epitopes, the neo-epitopes resulting from cancer specific somatic mutations in a tumor specimen of a cancer patient, or a nucleic acid encoding the polypeptide) and claim 23 (The vaccine according to claim 22, wherein the polypeptide further (!) comprises epitopes not containing cancer specific somatic mutation which are expressed by cancer cells)) is not new and not inventive because of my DE2012015806 (from 2012) for individualized anticancer fusion proteins, as well as because of my patent documents mentioned above, especially DE10162870.

Alexander Cherkasky

Email: alexcherkasky@googlemail.com